Oncologix Tech Statistics
Total Valuation
Oncologix Tech has a market cap or net worth of 166,247.
| Market Cap | 166,247 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Oncologix Tech has 1.66 billion shares outstanding.
| Current Share Class | 1.66B |
| Shares Outstanding | 1.66B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +203.65% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.04 |
| PB Ratio | -0.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.28
| Current Ratio | 0.28 |
| Quick Ratio | 0.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.82 |
| Interest Coverage | -0.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -11.83% |
| Return on Invested Capital (ROIC) | -20.87% |
| Return on Capital Employed (ROCE) | 72.86% |
| Revenue Per Employee | 24,116 |
| Profits Per Employee | -9,159 |
| Employee Count | 191 |
| Asset Turnover | 1.47 |
| Inventory Turnover | 42.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.00% in the last 52 weeks. The beta is 12.20, so Oncologix Tech's price volatility has been higher than the market average.
| Beta (5Y) | 12.20 |
| 52-Week Price Change | -50.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 43.51 |
| Average Volume (20 Days) | 422,126 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.79 |
Income Statement
In the last 12 months, Oncologix Tech had revenue of 4.61 million and -1.75 million in losses. Loss per share was -0.01.
| Revenue | 4.61M |
| Gross Profit | 981,045 |
| Operating Income | -592,264 |
| Pretax Income | -1.75M |
| Net Income | -1.75M |
| EBITDA | -572,245 |
| EBIT | -592,264 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 120,485 in cash and 3.33 million in debt, giving a net cash position of -3.21 million or -0.00 per share.
| Cash & Cash Equivalents | 120,485 |
| Total Debt | 3.33M |
| Net Cash | -3.21M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -1.19M |
| Book Value Per Share | -0.00 |
| Working Capital | -3.35M |
Cash Flow
In the last 12 months, operating cash flow was -570,250 and capital expenditures -2,033, giving a free cash flow of -572,283.
| Operating Cash Flow | -570,250 |
| Capital Expenditures | -2,033 |
| Free Cash Flow | -572,283 |
| FCF Per Share | -0.00 |
Margins
Gross margin is 21.30%, with operating and profit margins of -12.86% and -37.98%.
| Gross Margin | 21.30% |
| Operating Margin | -12.86% |
| Pretax Margin | -37.98% |
| Profit Margin | -37.98% |
| EBITDA Margin | -12.42% |
| EBIT Margin | -12.86% |
| FCF Margin | n/a |
Dividends & Yields
Oncologix Tech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -97.56% |
| Shareholder Yield | -97.56% |
| Earnings Yield | -1,052.21% |
| FCF Yield | -344.24% |
Stock Splits
The last stock split was on May 19, 2011. It was a reverse split with a ratio of 0.25.
| Last Split Date | May 19, 2011 |
| Split Type | Reverse |
| Split Ratio | 0.25 |
Scores
Oncologix Tech has an Altman Z-Score of -18.38. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -18.38 |
| Piotroski F-Score | n/a |